



ABC NEWSLETTER

CURRENT EVENTS AND TRENDS IN BLOOD SERVICES

Visit ABC's Web site at: www.americasblood.org

2019 #19

June 7, 2019

INSIDE:

Undetectable Does Not Equal Untransmittable for HIV and Blood Transfusion.....	2
Upcoming ABC Webinars – Don't Miss Out!.....	3
2019 Summer Summit & MD Workshop Registration Opens.....	4
Member Feedback Sought on AABB Proposed 32 nd Edition of Standards.....	4
ABC 2019 Meetings & Workshops	4
RECENT REVIEWS	5
PEOPLE	5
MEMBER NEWS.....	5
GLOBAL NEWS	7
COMPANY NEWS	8
STOPLIGHT®: Status of America's Blood Centers' Blood Supply ..	8
CALENDAR.....	9
POSITIONS.....	9

Congress Passes PAHPA: Role of Blood Centers Recognized

Congress has passed the Pandemic and All-Hazards Preparedness and Advancing Innovation Act (PAHPA) following approval in the U.S. House of Representatives this week. The bill ([S.1379](#)) now awaits President Trump's signature which is expected in the near future. America's Blood Centers (ABC) and its members have supported this broad legislation that drives the nation's disaster planning and readiness activity. This marks the first time-ever that the sweeping preparedness and response legislation specifically recognizes the role of blood centers, calling for action in support of a safe and available blood supply through three important provisions for blood centers:

- inclusion of blood centers as stakeholders that the U.S. Department of Health and Human Services Assistant Secretary for Preparedness and Response (ASPR) must consult in disaster planning;
- recognition of financial implications borne by blood centers for such work; and
- a report to Congress from HHS within one year of the bill's enactment regarding recommendations for supporting an adequate blood supply.

“The Pandemic and All-Hazards Preparedness and Advancing Innovation Act is critically important legislation that works to make our nation better prepared for and able to keep Americans safer in response to natural disasters or biological, chemical, radiological or nuclear threats to our public health and national security,” said Rep. Susan Brooks (R-Ind.) a cosponsor of the bill in a news [release](#). “I am proud this bipartisan legislation is now on its way to the President's desk to be signed into law because it will ensure our health care professionals are trained to respond to possible pandemic outbreaks, prioritize the further development of our national stockpile of vaccines, medical equipment and diagnostics, and establish new advisory groups focused on protecting vulnerable populations such as senior citizens and people with disabilities during public health threats and emergencies.”


PAHPA expired in September of 2018 as the House and Senate worked to reach a compromise on the legislation that reauthorizes funding for public health preparedness, bioterrorism, and agencies such as BARDA. “The Pandemic and All-Hazards Preparedness and Advancing Innovation Act better equips our federal agencies to respond to new and emerging threats that jeopardize our national security and public health,” added bill cosponsor Rep. Anna Eshoo (D-Calif). “I applaud the House and Senate's bipartisan commitment to strengthening our nation's existing preparedness and response programs, and I look forward to the President signing this important bill into law.”

(continued on page 2)

Congress Passes PAHPA (continued from page 1)

ABC previously signed-on to multiple coalition [letters](#), joining more than 60 organizations, sent to congressional leadership encouraging passage of PAHPA in addition to ABC members advocating on Capitol Hill with their members of Congress during ABC's annual Advocacy Day in March. "This was long overdue, and sorely needed," said Rep. Greg Walden (R-Ore.) ranking member of the House Energy & Commerce Committee in a news [release](#). "The Pandemic and All-Hazards Preparedness and Advancing Innovation Act (PAHPA) is a longstanding, bipartisan national security priority. While PAHPA should have been approved months ago, I'm glad our nation's public health infrastructure programs have been reauthorized and extended so that our federal, state, and local officials have the tools they need to respond quickly and effectively to emerging and ongoing threats – whether they are natural or man-made."

ABC thanks all members that have supported both ABC's and the blood community's advocacy efforts in encouraging Congress to pass this legislation.

(Sources: Rep. Susan Brooks News [Release](#), 6/4/19; House Energy & Commerce Committee News [Release](#), 6/4/19; Coalition [Letter](#), 3/22/19) 

Undetectable Does Not Equal Untransmittable for HIV and Blood Transfusion

A recent commentary published in *Vox Sanguinis* highlights concerns about transfusion transmission of HIV from blood donors using pre-exposure prophylaxis (PrEP) antivirals. It addresses the results of the PARTNER2 study that evaluated the protective effect of suppressive HIV antiretroviral therapy for HIV-negative men who have sex with other men (MSM) and found no HIV transmissions among almost 77,000 condomless sex acts. According to the authors of the commentary, "the data further support the validity of the U=U or 'undetectable = untransmittable' campaign (<https://www.preventionaccess.org/consensus>), that is that HIV-infected individuals on antiretroviral therapy who maintain a viral load below 200 copies/ml for 6 months have a negligible risk of transmitting HIV to their sexual partners."

The authors state that this data does not support extrapolation to the risk of HIV transmission by transfusion in their opinion due to "the larger inoculum and intravenous route of administration." They cite a study by Kleinman, *et al.* that correlated the infectivity of HIV in cases reported in the years 1999 -2009 where "there were 10 HIV seroconverting donors, among whom three [were not tested by] NAT and seven were tested by minipool NAT and found to be negative. Fifteen patients received blood products "two weeks to six months before seroconversion was detected. HIV occurred in 11 (73.3 percent) of the 15 recipients. Viral loads were determined for 7 of 10 donor units and found to be 50–250 HIV RNA copies/ml." Additionally, they note the importance that "in this context any transfusion of more than 5 ml of plasma from an individual with a viral load of 199 copies/ml could lead to HIV transmission."

(continued on page 3)

The *ABC Newsletter* (ISSN #1092-0412) is published by America's Blood Centers® and distributed by e-mail. Contents and views expressed are not official statements of ABC or its Board of Directors. Copyright 2019 by America's Blood Centers. Reproduction of the *ABC Newsletter* is forbidden unless permission is granted by the publisher. (ABC members need not obtain prior permission if proper credit is given.)

ABC advocates for and advances policies that promote the role of independent blood centers in providing life-saving blood products and recognize the continuous need for a safe and robust blood supply. ABC exists to advocate for laws and regulations recognizing the essential role that independent blood centers play in the healthcare system; promote partnerships, policies and programs that increase awareness about the need for blood donation; and serve as a thought-leader in the advancement of evidence-based medical and scientific solutions related to health and safety.

America's Blood Centers

Chief Executive Officer: Kate Fry

Chief Medical Officer: Rita Reik

Editor: Mack Benton

Subscriptions Manager: Leslie Maundy

Annual Subscription Rate: \$390

Send subscription queries to

lmaundy@americasblood.org

America's Blood Centers

1717 K St. NW, Suite 900, Washington, DC 20006

Phone: (202) 393-5725

Send news tips to newsletter@americasblood.org.



Undetectable Does Not Equal Untransmittable (continued from page 2)

Another analysis performed by Vermeulen, *et al.* is referenced in the commentary. That “10-year analysis of HIV individual donation NAT (ID-NAT) in South Africa which described 481 window period yield cases including the first transfusion transmission attributed to a red blood cell associated with an ID-NAT negative donation.” The plasma bag was unavailable for a determination of viral load, however the manufacturer’s 95 percent lower limit of detection for the assay was 12.7 copies/ml and “sufficient to transmit HIV in this case.”

The authors further state that “U≠U for blood transfusion” and emphasized that prospective donors could be confused and not correctly assess their own HIV risk of transmission. Individuals that are known to be infected with HIV may assume that they are incapable of infecting others through blood donation. “Where universal HIV antibody testing applies, unless there is a test failure, this is not a significant blood safety risk, since HIV antibody levels in established HIV infection should make these individuals readily detectable. However, any increase in the number of HIV-infected donors attending to donate has negative implications for blood services including a marginal increased residual risk associated with erroneous issue of an HIV-infected donation. Furthermore, additional follow-up, counselling, testing and notification requirements of a HIV-infected donor are operationally resource intensive.” The commentary adds that donors using PrEP antivirals may also incorrectly believe they are incapable of acquiring HIV. “The potential for failure of PrEP to prevent acquisition of HIV carries potential for a donor on PrEP to be in the window period, and can transmit HIV by transfusion.” In conclusion, the authors suggest that “it was important to get the message across U≠U for blood donation so prospective donors with HIV or at higher risk of HIV do not self-risk assess and come to donate because they perceive they are not at risk of transmitting HIV.” They note that changes in the epidemiology of HIV transmission, strategies for prevention, and public health messaging will continue to present challenges for the transfusion medicine community and regulators to appropriately communicate and balance safety and evidence-based donor selection criteria.

Source: Gosbell, I.B., Hoad, V.C., Styles, C.E., *et al.* Undetectable does not equal untransmittable for HIV and blood transfusion. *Vox Sanguinis*.2019. Doi: [10.1111/vox.12790](https://doi.org/10.1111/vox.12790).

Contributed by Richard Gammon, MD, Medical Director at OneBlood 💧



Upcoming ABC Webinars – Don’t Miss Out!

- **Update on Biological Product Deviation Reports Webinar** – June 18th at 3 p.m. EDT. Additional details forthcoming!
- **QA Education Webinar – Change Management** – July 16th. Additional details forthcoming!
- **SMT Journal Club Webinar** – August 19. Additional details forthcoming!



America's Blood Centers®
It's About *Life*.

INSIDE ABC

The programs and services described in the Inside ABC section are available to ABC member blood centers and their staff only, unless otherwise specified.

2019 Summer Summit & MD Workshop Registration Opens

[Registration](#) has launched for the 2019 America's Blood Centers Summer Summit and Medical Directors Workshop in Denver, Col. July 30th – August 1st at the [Grand Hyatt Denver](#) (reserve rooms by [July 5th](#)). Don't miss an exclusive opportunity to take part in this year's newly designed meeting format that brings together thought leaders throughout the blood community to focus on the future of blood centers and the larger transfusion community. The theme of the Summer Summit is "Defining and Promoting Innovation in the Blood Sector." It will feature leaders from both within and outside the industry, case studies from your blood center peers, and engaging roundtable discussions to promote peer-to-peer collaboration in discussing the latest trends and issues impacting community blood centers. The meeting will also include the Medical Directors Workshop, the Summit Reception, and the Women-Inspiring-Leading-Learning High Tea Luncheon sponsored by Terumo BCT.

Member, government, hospital non-member, public, and emeritus registration rates are available [here](#). Contact [Leslie Maundy](#) for available sponsorship opportunities. Click [here](#) for additional meeting information.

Member Feedback Sought on AABB Proposed 32nd Edition of Standards

ABC is seeking the input of its member blood centers regarding feedback on AABB's proposed [32nd edition of Standards](#) for Blood Banks and Transfusion Services. Blood centers are encouraged to also submit independently to [AABB](#). The comment period is open until July 9, 2019.

(Source: MCN [19-039](#))

ABC 2019 Meetings & Workshops				
Meeting/Workshop	Dates	Location	Hotel/Hotel Rate	Registration Dates & Fees
Medical Directors Workshop	July 30 (precedes Summer Mtg)	Denver, Colorado	Grand Hyatt, \$239/night	Register by July 5! MD Workshop \$435 MD+Summer \$760
Summer Summit	July 31-August 1	Denver, Colorado	Grand Hyatt, \$239/night	Register by July 5! Summer \$655 Summer+MD \$760
Notes: For the most up-to-date information on all events, members of ABC may check the calendar on ABC's Member Site. Non-members may attend all events; information will be updated on ABC's Public Site .				



RECENT REVIEWS

Platelets or immunoglobulin (IVIg) to treat fetal and neonatal alloimmune thrombocytopenia (FNAIT)? A systematic review published in the *Journal of Perinatology* sought to explore the impact of postnatal FNAIT, a bleeding disorder that can be severe and found in an estimated 1 in 1,000 live births. Among the interventions discussed in the review to combat FNAIT are the use of either Human platelet antigen (HPA)-selected platelets, HPA-unselected, and/or IVIg as ways to improve platelet counts or decrease instances of severe hemorrhage and mortality. While the review “does support the conclusion that platelet transfusions, both selected and unselected, are effective in increasing the platelet count in newborns with FNAIT;” the authors suggest the possible existence of a platelet transfusion threshold while acknowledging that their review was limited by the available data. Furthermore, they state that the data quality did not allow for any determinations regarding if “there is added benefit” when administering IVIg with platelets (especially unselected).

Citation: Baker, J., Shehata, N., Bussel, J., et al. [Nature J. of Perinatology. Postnatal intervention for the treatment of FNAIT: a systematic review.](#) 2019 ♦

PEOPLE

Brad Bryan, PhD, MBA has been named interim chief executive officer (CEO) at Houchin Community Blood Bank. “I’m just honored that [the board of directors] would allow me to fill [the CEO] position,” said Dr. Bryan to [Bakersfield.com](#). “I think there’s a lot of great people here and it’s a great mission...[M]y plans are [to] empower our people and keep supporting the community. And make sure that we maintain strong relationships to Kern County.” He received his PhD in medical science from Texas A&M University and his MBA from the University of Massachusetts, Amherst. Additionally, Dr. Bryan holds a Bachelor of Science degree in biological sciences from Stephen F. Austin State University and a Master of Science degree in biochemistry from Texas A&M. He serves in the U.S. Coast Guard Reserve and joined Houchin Community Blood Bank in March as the director of Laboratory and Technical Services before being promoted to the role of chief operating officer, a position he will remain in while serving as interim CEO.



(Source: [Bakersfield.com](#), [Houchin CEO](#), 6/3/19) ♦

MEMBER NEWS

Global Blood Fund (GBF), a 501 (c)(3) charity founded by America’s Blood Centers member **Oklahoma Blood Institute**, has been awarded a \$22,500 grant from Terumo BCT. The grant will assist with GBF’s ongoing efforts to support and improve blood donor recruitment programs in Africa. “Terumo BCT has shown a generous commitment to leading the way for better transfusion care across the globe,” said Oklahoma Blood Institute CEO and GBF Chair John Armitage, MD in a news release. “This gift will allow Africa to build a much-needed foundation to recruit new blood donors and expand the availability of safe blood to areas where it is so desperately needed.” GBF intends to use the funds to help facilitate a distance learning donor recruitment and management education certification program through a series of 12 videocast lectures in partnership with the Africa Society for Blood Transfusion, and to support a predonation blood typing pilot program in Ghana. “Blood and cells connect us all, and at Terumo BCT, we are committed to our mission of ‘Contributing to Society Through Health-



(continued on page 6)

MEMBER NEWS (continued from page 5)

care' and increasing healthcare access to patients not only in our business operations but also in our giving," said Monte Smith, senior vice president of Strategic and Market Development and Chair of Terumo BCT's Charitable Giving Review Committee. "We are honored to support Global Blood Fund in its work to build capacity, improve donor education and increase a consistent supply of blood donors in resource-constrained countries to ultimately improve the healthcare system and impact patient lives."

(Source: GBF Announcement 6/6/19)



Vitalant Research Institute recently [announced](#) that it has been awarded multiple contracts as part the National Heart, Lung and Blood Institute's (NHLBI) Recipient Epidemiology and Donor Evaluation Study (REDS) now entering its 4th phase (REDS-IV-P). "Vitalant Research Institute is the only institute that has participated in REDS since its inception in 1989," said Michael Busch, MD, PhD, senior vice president of Research and Scientific Affairs at Vitalant and director of Vitalant Research Institute in a news release. "We are proud of this level of continuity of both our donor and recipient research contributions, as it is an achievement that no other research entity in the field holds. It also serves to showcase our expertise and dedication to innovation in transfusion medicine across the globe." REDS-IV-P will continue research exploring the safety and efficacy of blood transfusion in adults as well as children. Vitalant Research Institute will continue partnering with University of California (San Francisco) as a REDS hub, and will also work with the University of São Paulo Tropical Medicine Institute continuing an international program that evaluates the "the safety and effectiveness of transfusion strategies in a large cohort of patients with sickle cell disease which was established in REDS-III, and for continued evaluation of arboviral threats to blood safety" states the release. Other ABC members that are a part of REDS-IV include **New York Blood Center** and **Versiti Blood Research Institute**, with the American Red Cross and Yale participating as well.

(Source: Vitalant News [Release](#), 5/9/19)

Bloodworks Northwest and Legacy Emanuel Medical Center and Randall Children's Hospital have [partnered](#) using the [Thank-The-Donor™](#) program as a way for blood recipients to thank blood donors anonymously. **Oklahoma Blood Institute** developed and licensed the platform. The technology allows patients to send thank you messages anonymously sharing their gratitude to connect with donors and serve as source of future inspiration. "Thank-The-Donor™ is a free tool enabling one-way messages of gratitude to be sent from a blood recipient or their loved ones to a blood donor while maintaining the privacy of both parties," said officials from Legacy Emanuel Medical Center according to KATU-2 (Portland, Ore.). Bloodworks Northwest becomes the first blood center in the pacific northwest region of the U.S. to implement Thank-The-Donor™.

(Source: KATU-2, [Program to anonymously allow Portland patients to message blood donors](#), 5/6/19) ♦

We Welcome Your Letters

The *ABC Newsletter* welcomes letters from its readers on any blood-related topic that might be of interest to ABC members. Letters should be kept relatively short and to the point, preferably about a topic that has recently been covered in the *ABC Newsletter*. Letters are subject to editing for brevity and good taste and published after editorial review. Please send letters to the Editor at newsletter@americasblood.org or fax them to (202) 899-2621. Please include your correct title and organization as well as your phone number. The deadline for letters is Wednesday to make it into the next newsletter.



GLOBAL NEWS

Bluebird Bio has received clearance from the European Commission (EC) for the first approved gene therapy (ZYNTEGLO™) to treat transfusion-dependent beta thalassemia (TDT) patients older than the age of 12. “EC approval of ZYNTEGLO™ is a milestone that represents the dedication and commitment of clinical investigators, healthcare providers, patients and their families, and our employees, all of whom have helped advance this treatment from concept to an approved therapy,” said Bluebird CEO Nick Leschly in a company news [release](#). “Our first product approval is a humbling moment for all of us at bluebird, and we look forward to continuing our work with the TDT community and health systems to bring this important treatment to patients.” According to a report in *Bloomberg*, Bluebird anticipates approval for use in the U.S. in 2020 and intends to cap the cost of the one-time therapy at \$2.1 million though a report from *Reuters* in March suggested the price tag to be closer to \$800K per patient. The clearance followed a European Medicines Agency panel’s recommendation in favor of approving the therapy. “We welcome European Commission authorization for the first gene therapy for TDT. This achievement means the TDT community now has another treatment option that may provide new hope for people living with TDT who have been managing their disease through chronic transfusions,” said Dr. Androulla Eleftheriou, executive director of Thalassaemia International Federation. “Undoubtedly, this is not the end of the road, but merely the beginning, and TIF is ready to collaborate with all involved stakeholders to help ensure accessibility for as many appropriate patients as possible.”

(Sources: Bluebird Bio News [Release](#), 6/3/19; *Bloomberg*, [Bluebird Bio’s first gene therapy wins approval in Europe](#), 6/3/19; *Reuters*, [EMA panel recommends approval of Bluebird Bio’s first gene therapy](#); 3/29/19)

The South African National Blood Service (SANBS) will begin using drones to deliver blood products to hospitals in remote locations. According to the recent [announcement](#), the TRON Unmanned Aerial Vehicle can reach speeds of 160 km/h in-flight while traveling at an altitude of 100 m servicing hospitals within a 100 km radius allowing the blood service to distribute blood products to hospitals in a new and efficient manner. “We believe that this is an innovative step in the history of blood transfusion,” said SANBS CEO Jonathan Louw, MBChB, MBA. “SANBS is determined to improve rapid access to lifesaving blood products in rural areas through the use of drone technology. Our concept is globally unique in that we will provide two-way logistics; patients can receive emergency ‘O negative’ blood from one of our blood banks via drone. The same drone can take that patient’s blood sample to the blood bank for comprehensive cross-matching and then safely and rapidly deliver compatible blood back to the patient.” The drones will be able to deliver as many as four units of blood.



Photo courtesy of SANBS

(Source: SANBS News [Release](#), 5/29/19)

Canada’s largest private sector union, Unifor, continues to call for Health Canada to eliminate the deferral of men who have sex with other men (MSM). “A ban is a ban. Canada faces a chronic shortage of blood and organ donation, but still turns away donors based on sexual orientation,” said Unifor National President Jerry Dias. “We need blood donation policies that ensure a safe supply without reinforcing discrimination.” Last month, Canadian regulators announced that the 12-month MSM deferral would be reduced to three months. Renaud Gagné, director of Unifor Quebec added, “[w]hile this shift brings us closer to an end to the ban, we encourage Health Canada to finally make the shift to a behaviour-based survey for all potential donors.”

(Source: Unifor News [Release](#), 5/10/19)



COMPANY NEWS

Cerus Corp. has unveiled a new logo and headquarters as part of a new corporate [branding](#) campaign emphasizing the company’s role and commitment to “proactively protecting” the blood supply world-wide. “After over two decades of sustained effort to support blood centers and national transfusion services in adopting our Intercept system as their standard of care, Cerus is entering the next chapter of our planned growth and evolution. The new corporate brand and global headquarters provide Cerus with an improved foundation going forward,” said Cerus President and CEO William ‘Obi’ Greenman in a news [release](#). “Since our inception, as we expanded operations, we grew into three separate buildings in Concord. The new office provides a scalable workspace to support our multi-year growth strategy, while our new brand identity embodies our goal to be a world class partner for an increasing number of blood centers around the globe.” Cerus’ new corporate headquarters will be 1220 Concord Ave. in Concord, Calif.





(Source: Cerus News [Release](#), 6/3/19) ♦

STOPLIGHT®: Status of America’s Blood Centers’ Blood Supply

Total ABC Red Cell Inventory

Percent of Regional Inventory at 2 Days Supply or Less, June 5, 2019



Percent of Total ABC Blood Supply Contributed by Each Region
 East: 20%; Midwest: 25%; South: 24%; West: 31%

Daily updates are available at:
www.AmericasBlood.org

ABC Calendar of Events

ABC offers a variety of meetings, workshops and virtual opportunities for education and networking as well as participation in ABC business. The [calendar of events](#) includes annual and summer meetings, board meetings, workshops, and webinars, and details will be updated as confirmed. We look forward to your support and participation!

CALENDAR

Note to subscribers: Submissions for a free listing in this calendar are welcome. Send information to Leslie Maundy by e-mail (lmaundy@americasblood.org) or by fax to (202) 899-2621. (For a more detailed announcement in the weekly "Meetings" section of the newsletter, please include program information.)

2019

July 30-Aug. 1. **2019 ABC Medical Directors Workshop & Summer Summit, Denver, Colo.** More details coming soon.

May 19-21. **2020 ADRP Conference, Phoenix, Ariz.** More details coming soon. 💧

CLASSIFIED ADVERTISING

Classified advertisements, including notices of positions available and wanted, are published free of charge for a maximum of three weeks per position per calendar year for ABC institutional members. There are charges for non-members: \$139 per placement for ABC Newsletter subscribers and \$279 for non-subscribers. A six (6) percent processing fee will be applied to all credit card payments. Notices ordinarily are limited to 150 words. To place an ad, contact Leslie Maundy at the ABC office. Phone: (202) 654-2917; fax: (202) 899-2621; e-mail: lmaundy@americasblood.org.

POSITIONS

Operations Manager. Blood Assurance is seeking an Operations Manager to manage our collection efforts in greater Chattanooga, TN and surrounding areas. This position will be responsible for operational oversight of collection services for multiple collection teams in an assigned territory. Supervises staff in coordination with other department leaders and ensures compliance with all Standard Operating Procedures, FDA and AABB regulations. Monitors performance in the areas of productivity, proficiency and customer service. A bachelor's degree with some prior supervisory/ management experience in blood banking is required. Advanced skills in leadership, teamwork, analytics and communications are also required. Blood Assurance offers a competitive base wage with healthcare benefits and a 401K retirement plan. Qualified candidates are encouraged to submit an online employment application for consideration at www.bloodassurance.org. Blood Assurance is an Equal Opportunity Employer and a Tobacco Free Workplace.

Director of Technical Services. Manages laboratory employees in testing and preparation of blood products and manages Hospital Services' employees for distribution of products. Supervises Quality Assurance functions to ensure accurate and reliable work; enforces Safety policies; and encourages and trains according to cGMPs. Oversees Technical Services' compliance with the FDA, AABB and state regulations for blood centers. Promotes positive customer relations in an effort to achieve customer satisfaction and repeat business. Assists other Senior Management Team members in carrying out Sheppard's mission and goals. Qualifications: Minimum of associates degree in a biological science; Medical Technology or Clinical Laboratory Science certification awarded by the American Society of Clinical Pathology or equivalent; minimum of an associate degree in a Biological Science, Medical Technology or Clinical

Laboratory Science certification awarded by the American Society of Clinical Pathology or equivalent. At least five (5) years progressive experience in management, SOP writing and FDA compliance. Experience in hospital transfusion medicine/blood bank. Please upload a cover letter, resume, relevant documentation and complete an application on our website, www.shepearblood.org. Contact Dahmer Clegg, HR Coordinator, at dclegg@shepearblood.org, if you have any questions. Sheppard is an EEO for individuals with Disabilities & Protected Veterans.

Medical Director. If you have a passion to join a team that is providing cutting-edge medical expertise in the areas of blood banking, transfusion medicine, immunohematology reference laboratories, therapeutic apheresis, cellular therapy and research, consider joining OneBlood as a **Medical Director**. Qualified candidates should possess a minimum of three years' experience and a M.D. or D.O. degree with board certification in Clinical Pathology, Internal Medicine or Hematology and subspecialty board certified in Blood Banking/Transfusion Medicine by a Board Registry recognized by the American Board of Medical Specialties. Appropriate state licenses will be required as needed. Must meet the eligibility requirements to obtain appointments at hospitals served by OneBlood. This position includes the option of free medical coverage with a competitive benefit package, 403(b) retirement plan with company contribution PLUS a company match, company vehicle lease/allowance, paid holidays, and much more. This position will be based out of the Jacksonville, Florida area, with some of the most gorgeous beaches in the nation! If you want to

(continued on page 10)



POSITIONS (continued from page 9)

join our life saving mission and team of dedicated employees, visit our *Careers* page at www.oneblood.org to learn more. OneBlood, Inc., a proven leader in blood banking, is an Equal Opportunity Employer/Vet/Disability.

Laboratory Services Manager. LifeSouth Community Blood Centers is currently seeking a skilled individual for a Laboratory Services Manager position in our Immunohematology Reference Laboratory in Gainesville, FL. This position is responsible for overseeing all laboratory testing activities performed in the LifeSouth facility. This includes meeting the needs of customers for accurate, timely and high-quality immunohematology reference laboratory testing and services. This position is also responsible for compliance with established laboratory policy and with applicable governmental regulatory requirements from CLIA, FDA, AABB, HIPAA and state licensing regulations. Bachelor's degree in clinical laboratory, chemical or biological science required. SBB Certification required. Five years of clinical laboratory experience at a licensed, certified or accredited facility required. Previous management experience required. Master's degree may compensate for less experience. Relocation expenses negotiable. Background check and drug test required. Equal Opportunity/Affirmative Action Employer/DFWP/Tobacco Free. VEVRAA Federal Contractor. Follow this link to apply: <https://lifesouth.careerplug.com/jobs/901033/apps/new>.

Clinical Lab Supervisor (San Francisco, CA). Since 1941, Vitalant has proudly served as a leader in the blood banking industry. We are a globally-recognized leader in blood transfusion medicine. Requirements: Bachelor's degree. Must satisfy CLIA requirements for High Complexity Testing. Certification as a Medical Technologist or Specialist in Blood Banking (SBB) by a recognized certifying organization. Seven years clinical laboratory testing experience. Two years supervisor experience required. Two years IRL experience preferred. Apply [here](#). EOE

Medical Director. Provide transfusion medicine (TM) clinical care at Heartland Blood Center (HBC) and its associated hospitals in the scope noted below, as well as effort in leadership of the Immunohematology Reference Laboratory (IRL) as Medical Director at HBC/Versiti. Key components of this position would comprise TM consultation and oversight of blood management at HBC and Versiti partner hospitals, as well as participation in educational initiatives and clinical/applied research within both Versiti blood centers and their affiliated health systems. Primary Responsibilities: Oversees blood donor center collections in the Chicagoland and various areas of Indiana. Provides medical direction, including compliance with local, state, and federal regulations and accreditation agencies, for blood center and transfusion services at Versiti affiliated hospitals in Illinois and Indiana. IRL Medical Director for HBC, providing oversight of IRL laboratory staff technical duties and working with Versiti and HBC laboratory management to provide education and skill advancement. Education and Licenses: M.D. or D.O. Degree. Board certified in pathology (AP/CP or CP only), internal medicine, or pediatrics (with subspecialty boards in hematology). Board certified/board eligible in Blood Banking/Transfusion Medicine (American Board of Pathology—ABP). Current or eligible for medical licenses in Illinois, Wisconsin, Indiana, Michigan and Ohio. Experience/Certifications: Demonstrated experience in both 1) pathology/laboratory medicine or hematology and 2) transfusion medicine. Ability to write lectures and articles using original or innovative techniques or styles; excellent presentation skills with capacity to present to varied audiences. Click [here](#) to view the full job description and to apply.💧